Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ciclosporin, quantity: 100 mg - capsule, soft - excipient ingredients: propylene glycol; iron oxide black; titanium dioxide; corn glycerides; dl-alpha-tocopherol; glycerol; gelatin; ethanol; peg-40 hydrogenated castor oil; hypromellose; purified water; isopropyl alcohol; cochineal; aluminium chloride; sodium hydroxide - cyclosporin sandoz is indicated as an immunosuppressive agent for the prevention of graft rejection following kidney, liver and heart allogeneic transplantation. for induction and/or maintenance of remission in the nephrotic syndrome. cyclosporin is not a first-line agent. its use should be restricted to occasions when steroids and cytostatic drugs have failed, or are not tolerated, or are considered inappropriate, and when renal function is unimpaired (see precautions). for the treatment of severe, active rheumatoid arthritis in patients for whom classical slow-acting antirheumatic agents (including methotrexate) are inappropriate or ineffective. in patients with severe psoriasis in whom conventional therapy is ineffective or inappropriate and the disease has caused a significant interference with the quality of life. for the treatment of severe atopic dermatitis when other treatment is ineffective or inappropriate. careful monitoring of all cyclosporin-treated patients is mandatory. cyclosporin should only be used by medical practitioners who are experienced in the use of immunosuppressive therapy (see "precautions").

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ciclosporin, quantity: 50 mg - capsule, soft - excipient ingredients: propylene glycol; ethanol; glycerol; titanium dioxide; peg-40 hydrogenated castor oil; gelatin; corn glycerides; dl-alpha-tocopherol; hypromellose; purified water; isopropyl alcohol; cochineal; aluminium chloride; sodium hydroxide - cyclosporin sandoz is indicated as an immunosuppressive agent for the prevention of graft rejection following kidney, liver and heart allogeneic transplantation. for induction and/or maintenance of remission in the nephrotic syndrome. cyclosporin is not a first-line agent. its use should be restricted to occasions when steroids and cytostatic drugs have failed, or are not tolerated, or are considered inappropriate, and when renal function is unimpaired (see precautions). for the treatment of severe, active rheumatoid arthritis in patients for whom classical slow-acting antirheumatic agents (including methotrexate) are inappropriate or ineffective. in patients with severe psoriasis in whom conventional therapy is ineffective or inappropriate and the disease has caused a significant interference with the quality of life. for the treatment of severe atopic dermatitis when other treatment is ineffective or inappropriate. careful monitoring of all cyclosporin-treated patients is mandatory. cyclosporin should only be used by medical practitioners who are experienced in the use of immunosuppressive therapy (see "precautions").

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ciclosporin, quantity: 25 mg - capsule, soft - excipient ingredients: titanium dioxide; peg-40 hydrogenated castor oil; propylene glycol; glycerol; corn glycerides; iron oxide black; dl-alpha-tocopherol; gelatin; ethanol; hypromellose; purified water; isopropyl alcohol; cochineal; aluminium chloride; sodium hydroxide - cyclosporin sandoz is indicated as an immunosuppressive agent for the prevention of graft rejection following kidney, liver and heart allogeneic transplantation. for induction and/or maintenance of remission in the nephrotic syndrome. cyclosporin is not a first-line agent. its use should be restricted to occasions when steroids and cytostatic drugs have failed, or are not tolerated, or are considered inappropriate, and when renal function is unimpaired (see precautions). for the treatment of severe, active rheumatoid arthritis in patients for whom classical slow-acting antirheumatic agents (including methotrexate) are inappropriate or ineffective. in patients with severe psoriasis in whom conventional therapy is ineffective or inappropriate and the disease has caused a significant interference with the quality of life. for the treatment of severe atopic dermatitis when other treatment is ineffective or inappropriate. careful monitoring of all cyclosporin-treated patients is mandatory. cyclosporin should only be used by medical practitioners who are experienced in the use of immunosuppressive therapy (see "precautions").

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

pharmathen international s.a. - isotretinoin - capsules soft - 10mg

Malta - English - Medicines Authority

teva b.v. swensweg 5, 2031 ga haarlem, netherlands - dutasteride - soft capsule - dutasteride 0.5 mg - urologicals

Malta - English - Medicines Authority

stada arzneimittel ag stadastraße 2-18, 61118 bad vilbel, germany - dutasteride - capsule - dutasteride 0.5 mg - urologicals

Ireland - English - HPRA (Health Products Regulatory Authority)

laboratoires besins international - progesterone - capsule, soft - 100 milligram(s) - progesterone

Ireland - English - HPRA (Health Products Regulatory Authority)

pharmafile limited - colecalciferol - capsule, soft - 1000 international unit(s) - vitamin d and analogues; colecalciferol

Ireland - English - HPRA (Health Products Regulatory Authority)

pharmafile limited - colecalciferol - capsule, soft - 10000 international unit(s) - vitamin d and analogues; colecalciferol

Ireland - English - HPRA (Health Products Regulatory Authority)

pharmafile limited - colecalciferol - capsule, soft - 20,000 international unit(s) - vitamin d and analogues; colecalciferol